These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35380480)

  • 1. Cost-effectiveness of future lockdown policies against the COVID-19 pandemic.
    Gandjour A
    Health Serv Manage Res; 2023 Feb; 36(1):51-62. PubMed ID: 35380480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Was EU's COVID-19 vaccine procurement strategy irrational? A re-analysis based on cost-effectiveness considerations.
    Gandjour A
    BMC Health Serv Res; 2022 Nov; 22(1):1410. PubMed ID: 36434631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Metric of Societal Burden Based on Virus Succession to Determine Economic Losses and Health Benefits of China's Lockdown Policies: Model Development and Validation.
    Chen W; Zhang B; Wang C; An W; Guruge SK; Chui HK; Yang M
    JMIR Public Health Surveill; 2024 Jun; 10():e48043. PubMed ID: 38848555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies.
    Fu Y; Zhao J; Wei X; Han P; Yang L; Ren T; Zhan S; Li L
    Front Public Health; 2022; 10():917732. PubMed ID: 35928479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany.
    Gandjour A
    Appl Health Econ Health Policy; 2021 Mar; 19(2):181-190. PubMed ID: 33433853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Siqueira PG; Duarte HO; Moura MDC
    Vaccine; 2022 Jun; 40(28):3851-3860. PubMed ID: 35610105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants.
    Cheng HL; Lim SM; Jia H; Chen MW; Ng SY; Gao X; Somani J; Sengupta S; Tay DMY; Chua PWL; R A; Ling SYH; McBee ME; Young BE; Sikes HD; Preiser PR
    Microbiol Spectr; 2022 Oct; 10(5):e0225722. PubMed ID: 36069616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
    Tanaka M; Okubo R; Hoshi SL; Ishikawa N; Kondo M
    Vaccine; 2022 Feb; 40(7):1010-1018. PubMed ID: 35039195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States.
    Li R; Liu H; Fairley CK; Zou Z; Xie L; Li X; Shen M; Li Y; Zhang L
    Int J Infect Dis; 2022 Jun; 119():87-94. PubMed ID: 35338008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for the economic evaluation of COVID-19 pandemic response policies.
    Chua BWB; Huynh VA; Lou J; Goh FT; Clapham H; Teerawattananon Y; Wee HL
    BMJ Open; 2021 Sep; 11(9):e051503. PubMed ID: 34521677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should the COVID-19 lockdown be relaxed or intensified in case a vaccine becomes available?
    Buratto A; Muttoni M; Wrzaczek S; Freiberger M
    PLoS One; 2022; 17(9):e0273557. PubMed ID: 36054113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The COVID-19 pandemic posed many dilemmas for policymakers, which sometimes resulted in unprecedented decision-making.
    Ash N; Triki N; Waitzberg R
    Isr J Health Policy Res; 2023 Apr; 12(1):13. PubMed ID: 37072814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA.
    Li R; Lu P; Fairley CK; Pagán JA; Hu W; Yang Q; Zhuang G; Shen M; Li Y; Zhang L
    Appl Health Econ Health Policy; 2024 Jan; 22(1):85-95. PubMed ID: 37910314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context.
    Debrabant K; Grønbæk L; Kronborg C
    Clin Drug Investig; 2021 Nov; 41(11):975-988. PubMed ID: 34623627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
    de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
    BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.